AUSTIN, TEXAS, July 18, 2017 – Siva Therapeutics (“Siva”) is pleased to announce that its Targeted Hyperthermia™ technology has successfully passed through the first stages of nanoparticle characterization at the Frederick National Laboratory (FNL) for Cancer Research in Frederick, Md.
FNL’s Nanotechnology Characterization Laboratory (NCL) – a partnership with the U.S. Food and Drug Administration and the National Institute of Standards and Technology – is a world leader in the characterization of therapeutic nanoparticles, which helps pave the way for regulatory review of nanotechnologies intended for cancer therapies and diagnostics.
The NCL uses a three-tiered assay cascade to thoroughly characterize each nanomaterial strategy submitted to the lab for physical and chemical attributes, in vitro biological properties, and in vivo compatibility through preclinical toxicology, pharmacology, and efficacy studies. Through an application process, NCL offers preclinical characterization services to investigators nationwide who have developed promising nanotechnology-based cancer treatments. NCL’s assay cascade takes about a year to complete.
BOULDER, COLORADO, August 7, 2014 – Siva Therapeutics has had a manuscript accepted for publication in the Journal of Nanomaterials. The forthcoming paper, entitled “Photothermal therapy using gold nanorods and near-infrared light in a murine melanoma model increases survival and decreases tumor volume” by Mary Popp and colleagues, describes Siva’s approach to photothermal monotherapy for melanoma, using the aggressive B16F10 mouse melanoma model. The study also describes the tissue and gel models used to develop and calibrate the photothermal therapy approach.
BOULDER, COLORADO, March 18, 2014 – Siva Therapeutics (“Siva”) has initiated a research collaboration with SomaLogic, Inc. (Boulder, CO). The initial focus of the collaboration is to determine the ability of SomaLogic’s SOMAmer® (Slow-off Rate Modified Aptamer) reagents to actively target gold nanorods to solid tumors. Continue reading
BOULDER, COLORADO, January 23, 2014 – Siva Therapeutics Inc (‘Siva’) has initiated a research collaboration with Plexxikon Inc., of Berkeley, California. The focus of the collaboration is to evaluate the potential for synergistic effects between Zelboraf®, a cancer treatment approved for BRAF V600E mutation-positive metastatic melanoma discovered and co-developed by Plexxikon, and SivaRods™ photothermal therapy. Continue reading
BOULDER, COLORADO, July 10, 2013 – Siva Therapeutics Inc (‘Siva’) has generated very positive efficacy results in a challenging mouse melanoma model, using SivaRods™ photothermal therapy. In the study, significant decreases in tumor volume and increased survival, relative to control animals, were seen. Continue reading
Boulder, Colorado, June 17, 2013 – Siva Therapeutics hosted an open house at its new facility in Boulder, CO. The open house included laboratory presentations of SivaRods Therapy in action. The Colorado BioScience Association visited and took several great pictures which you can find here: Continue reading
BOULDER, COLORADO, February 4, 2013 – Siva Therapeutics (‘Siva’) has been awarded a $250,000 Early Stage Company Grant from the Bioscience Discovery Evaluation Grant Program (BDEGP) administered by the Colorado Office of Economic Development and International Trade (COEDIT). Continue reading
BOULDER, COLORADO, December 3, 2012 –Siva Therapeutics has closed an initial angel financing round; this funding, together with a recent $350,000 grant from Breakout Labs, has enabled Siva to expand operations and to undertake a new series of studies on its nanotechnology enabled photothermal therapy. With this financing in place, Siva has hired a Bioengineer Continue reading
BOULDER, COLORADO, September 26, 2012 –Siva Therapeutics has been awarded a grant of $350,000 from the Thiel Foundation’s prestigious new program to fund scientific innovation, Breakout Labs. Continue reading
BOULDER, COLORADO, September 6, 2012 –Siva Therapeutics has signed an option agreement for a co-exclusive license to a published US patent application entitled ‘Gold Nanoparticle Conjugates and Uses Thereof’ with the Technology Transfer Office at the Colorado School of Mines (CSM). Continue reading